Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Effects of Gene Polymorphisms on Metabolic Features in Clozapine-treated Patients With Schizophrenia

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2011 by Taipei Medical University WanFang Hospital.
Recruitment status was:  Recruiting
Information provided by:
Taipei Medical University WanFang Hospital Identifier:
First received: March 24, 2011
Last updated: March 25, 2011
Last verified: March 2011
The investigators would like to know the association of gene polymorphisms and metabolic adversities in clozapine-treated patients with schizophrenia in Taiwan.

Schizoaffective Disorder

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Effects of Gene Polymorphisms on Metabolic Features in Clozapine-treated Patients With Schizophrenia

Resource links provided by NLM:

Further study details as provided by Taipei Medical University WanFang Hospital:

Estimated Enrollment: 80
Study Start Date: May 2010
Estimated Study Completion Date: April 2011
Detailed Description:
The atypical antipsychotics, such as olanzapine, risperidone, quetiapine, and ziprasidone, are effective in treating both the positive and negative symptoms in schizophrenia (Kelleher et al., 2002). However, atypical antipsychotics have been linked to several forms of morbidity, including obesity, hyperlipidemia, and type 2 diabetes mellitus (DM) (Bergman and Ader, 2005; Jin et al., 2004; Melkersson and Dahl, 2004). Compared with the general population, life expectancy in schizophrenic patients is shorter by as much as 20%, attributable to higher rates of suicide, accidental deaths, and natural causes such as cardiovascular disease and DM (Harris and Barraclough, 1998). Several studies have suggested that these metabolic abnormalities may lead to a greater vulnerability to cardiovascular disease and thus may contribute to the excessive mortality among schizophrenic patients.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
schizophrenia or schizoaffective disorder patients

Inclusion Criteria:

  • fulfilled DSM-IV criteria of schizophrenia or schizoaffective disorder
  • 18-65 year of age
  • receiving clozapine for at least 6 months

Exclusion Criteria:

  • diabetes mellitus patients
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01324167

Contact: Chun-Hsin Chen, MD 886-2-29307930 ext 53961

Taipei Medical University-WanFang Hospital Recruiting
Taipei, Taiwan
Contact: Chun-Hsin Chen, MD    886-2-29307930 ext 53961   
Sponsors and Collaborators
Taipei Medical University WanFang Hospital
Principal Investigator: Chun-Hsin Chen, MD Taipei Medical University WanFang Hospital
  More Information

Responsible Party: Chun-Hsin Chen, Department of Psychiatry, WanFang Hospital Identifier: NCT01324167     History of Changes
Other Study ID Numbers: 99037
Study First Received: March 24, 2011
Last Updated: March 25, 2011

Keywords provided by Taipei Medical University WanFang Hospital:
schizoaffective disorder

Additional relevant MeSH terms:
Psychotic Disorders
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
GABA Antagonists
GABA Agents processed this record on May 24, 2017